Arecor signs agreement with Hikma Pharma to develop new injectable medicine

Arecor will receive upfront and milestone payments as part of the deal, as well as the opportunity to commercialise the medicine outside of the US

Hikma Pharmaceuticals plc. - Arecor signs agreement with Hikma Pharmaceuticals to develop new injectable medicine

Arecor Ltd has inked an agreement with FTSE 100 firm Hikma Pharmaceuticals PLC (LON:HIK) to develop a new, ready-to-use injectable medicine.

The new product, to be announced prior to launch, will use Arecor’s Arestat drug formulation technology and is expected to be submitted to the US Food and Drug Administration for regulatory approval in 2021.

WATCH: Arecor's Sarah Howell discusses results from successful phase I insulin trial

Under the agreement, Arecor will receive an upfront payment as well as further compensation based on the achievement of development, regulatory and commercial milestones.

Hikma, meanwhile, will be responsible for the manufacturing and commercialisation of the product, although Arecor will retain the right to develop and commercialise the medicine outside of the US.

Sarah Howell, Arecor’s chief executive, said that Hikma had a “strong and respected US hospital market presence” and the firm was looking forward to the joint development of the product as part of “a broad collaboration” with the blue-chip firm.

Meanwhile, Riad Mishlawi, president of Hikma Injectables, said the company was “confident that Arecor's state-of-the-art development platform, combined with Hikma's strong manufacturing capabilities and excellent commercial team, with its broad relationships across US hospital systems, will bring an important new treatment option to patients and healthcare providers".

Shares in Hikma were 0.7% higher at 1,887.5p in early deals on Thursday.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...



Arecor's Sarah Howell discusses results from successful phase I insulin trial

Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Andrew Scott following the successful completion of the phase I trial for its ultra-rapid acting insulin for diabetics. She says the product was shown to have a favourable profile when compared with standard treatments and the...

on 17/12/19

2 min read